Association study of schizophrenia with variants in miR-137 binding sites by Curtis, D & Emmett, W
1 
 
Association study of schizophrenia with variants in miR-137 binding sites  
 
1,2David Curtis, 1,3,4Warren Emmett 
1. UCL Genetics Institute, University College London 
2. Centre for Psychiatry, Barts and the London School of Medicine and Dentistry 
3. The Francis Crick Institute 
4. Department of Molecular Neuroscience, UCL Institute of Neurology 
 
Correspondence: David Curtis, Darwin Building, Gower Street, London WC1E 6BT, UK. Phone 00 44 20 
7679 2212. Fax 00 44 20 7791 5201. d.curtis@ucl.ac.uk 
 
Conflict of interest 
The authors declare they have no conflict of interest. 
 
  
2 
 
Abstract 
There is strong cumulative evidence for the involvement of miR-137 and its targets in the aetiology of 
schizophrenia. Here we test whether variants, especially rare variants, in miR-137 binding sites are 
associated with schizophrenia in an exome-sequenced sample of 4225 cases and 5834 controls. Only a 
small proportion of binding sites were covered by the capture system which had been used. A weighted 
burden test using the 372 detected variants demonstrated an excess among cases significant at 
p=0.024. The sample size is too small to implicate individual variants or genes but overall this finding 
does provide some further support for the hypothesis that disruption of miR-137 binding sites can 
increase the risk of schizophrenia, perhaps by leading to over-expression of the target gene. We 
recommend that future exome sequencing studies should cover the untranscribed regions of genes, 
which contain the microRNA binding sites, in order that this potentially important pathogenic mechanism 
can be adequately investigated. 
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Introduction 
MicroRNAs are small RNA molecules which can bind to specific sites in the 3' untranscribed region 
(UTR) of transcripts of certain other genes, and these genes are described as the targets of the 
microRNA. As discussed recently (Olde Loohuis et al., 2017) markers for both the gene for the 
microRNA miR-137 and for the genes it targets demonstrate association with schizophrenia (Kwon et 
al., 2013; Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014). 
Experimentally, reducing or increasing miR-137 expression in rat hippocampal neurons identifies sets of 
regulated genes involved in neurodevelopmental processes and neuronal maturation, supporting the 
proposition that it acts as a critical gene network hub contributing to the pathophysiology of 
schizophrenia (Olde Loohuis et al., 2017). When microRNA binds to the 3’ UTR of a gene it suppresses 
transcription, so a variant in the binding site could interfere with this process and lead to over-
expression. Here, we investigate whether variants in the binding sites of miR-137 are more commonly 
found in exome-sequenced schizophrenia cases than controls.  
 
Material and methods 
The dataset analysed was downloaded from the dbGaP data repository and consisted of whole exome 
sequence variants from a Swedish schizophrenia association study containing 4968 cases and 6245  
controls (Genovese et al., 2016). As described elsewhere (Curtis, 2017), the dataset was subjected to 
quality control (QC) procedures including the removal of subjects who appeared to have a substantial 
Finnish component to their ancestry to leave a sample of 4225 cases and 5834 controls which appeared 
to be ethnically well-matched. When carrying out exome-sequencing, only the coding parts of the 
genome are sequenced using a capture procedure which is intended to cover the exons of all genes and 
which may partially cover the neighbouring UTRs.  As reported in the original paper, the subjects were 
sequenced in 12 waves. For all but the first wave the Agilent SureSelect Human All Exon v.2 Kit was 
used for the hybrid-capture procedure whereas for the first wave an earlier version was used. Predicted 
binding sites for miR-137 were obtained from microRNA.org (Betel et al., 2010). Excluding the Y 
chromosome, there were 8139 predicted binding sites, of which 1139 were covered by SureSelect. 
Variants in these regions were extracted and analysed by SCOREASSOC, which performs a weighted 
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burden test such that very rare variants are weighted 10 times higher than a common variant with 
observed MAF=0.5 (Curtis, 2012). Each subject receives a score consisting of the weighted sum of the 
variant alleles possessed by that subject at all sites and a t test is used to compare the scores between 
cases and controls.  
 
Results 
In the binding sites covered, 372 variants were found which passed QC procedures. On average, the 
weighted burden test scores were indeed higher for cases than controls (t=2.3, 10057 df, p=0.024), 
indicating that subjects with schizophrenia on average are more likely to have variants, especially rare 
variants, in miR-137 binding sites than controls. However the effect is at best modest and most variants 
occurred in only one or two subjects, while for others there were only small differences in frequencies 
between cases and controls. Thus, if the effect is real it is not possible to implicate specific genes or 
variants. For the purposes of illustration, it may be worth noting the results for two genes for which the 
difference was most marked, as shown in Table 1. A variant at 10:106027165, rs7589 in the 3' UTR of 
GSTO1, was heterozygous in 5 out of 4224 cases and none out of 5833 controls while the adjacent 
variant at 10:106027166, rs375727967, was heterozygous in a single additional case. A variant at 
19:58773876, in a miR137 binding site in the 3'UTR of ZNF544, was heterozygous in 17 out of 4205 
cases and 13 out of 5814 controls, yielding an odds ratio of 1.8. Another variant in the same binding site 
at 19:58773869, rs199600767, was heterozygous in an additional 2 cases and 1 control. The results for 
all variants are presented in Supplementary Table 1. 
 
Discussion 
Given that the weighted burden test is statistically significant, our results do provide some further 
support for the hypothesis that abnormalities in miR-137 functionality could be involved in the aetiology 
of schizophrenia. Disruption of a microRNA binding site could lead to increased gene expression, 
providing a mechanism for a dominant, gain of function effect. However, we would emphasise that the 
results are by no means conclusive and we did not observe a large excess of variants among cases. 
With the sample sizes used it is not possible to assign risk to individual variants and most, including 
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those in GST01 and ZNF544, are too rare to have been imputed in large GWAS samples 
(Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014). All six subjects with a 
variant in the GSTO1 binding site have schizophrenia. This gene codes for an omega class glutathione 
S-transferase and a previous study showed that patients with schizophrenia have reduced glutathione 
levels in cerebrospinal fluid (Do et al., 2000), although a recent association study of schizophrenia with 
markers for GSTO1 and other glutathione related genes was negative (Matsuzawa et al., 2009). These 
negative results would be expected if only rare variants at critical locations, including perhaps microRNA 
bindings sites, exerted a substantial effect. However, as Table 1 shows, the variant which occurs in five 
cases, rs7589, is very common in African subjects in ExAC, making it implausible that it confers a major 
risk for schizophrenia. ZNF544 belongs to the C2H2-type zinc-finger family and is involved in gene 
transcription. In a genome-wide association study of ADHD traits an intronic SNP, rs260461, was 
significant at p=10-5 (Lasky-Su et al., 2008) and in a methylome-wide study a CpG island near ZNF544 
was found to be hyper-methylated at birth in subjects with a high trajectory for ADHD symptoms (Walton 
et al., 2017) but there does not seem to be other external evidence to implicate this gene. We certainly 
do not make any strong claim that our study provides much support for the theory that disturbances of 
either glutathione metabolism or ZNF544 function are involved in schizophrenia aetiology but rather we 
highlight these results to illustrate the nature of the findings produced by studies of very rare variants 
detected by sequencing.  
 
We believe that the hypothesis that disruption of miR-137 binding sites could increase the risk of 
schizophrenia is attractive. However, with the most informative data currently available we can obtain at 
best modest support for this. Although larger sample sizes might provide more conclusive results, a 
major limitation of the current study is that only a minority of binding sites were covered by the capture 
procedure. We strongly recommend that future exome sequencing studies should routinely obtain full 
coverage for UTRs as well as exons so that the role of variants potentially affecting microRNA binding 
can be properly evaluated. 
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Table 1. Genotype counts and allele frequencies for variants in miR137 binding sites in the 3’ UTRs of 
GTSO1 and ZNF544. No subject was heterozygous for more than one variant. WT = homozygous wild 
type, het = heterozygous. (Totals are less than the overall sample sizes because some individual 
genotypes failed QC.) Odds ratios (OR) with standard errors were calculated according to the Statistical 
Algorithms in Review Manager 5 (Deeks and Higgins, 2007). Also shown are variant allele frequencies 
in non-Finnish European and African populations, as provided by ExAC (Lek et al., 2016). 
 Position Controls 
WT 
Controls 
het 
Cases 
WT 
Cases 
het 
OR 
(95% CI) 
MAF, 
European 
(Non-
Finnish) 
MAF, 
African 
GTSO1         
rs7589 10:106027165 5833 0 4219 5 15.2 
(0.8-275.1) 
0.00082 0.26 
rs375727967 10:106027166 5833 0 4223 1 4.1 
(0.2-101.7) 
0.000030 0 
ZNF544         
rs199600767 19: 58773869 5812 1 4200 2 2.8 
(0.3-30.5) 
0.00013 0 
rs200237099 19: 58773876 5801 13 4188 17 1.8 
(0.9-3.7) 
0.0012 0 
 
